Toulouse Cedex
Welcome,         Profile    Billing    Logout  
 9 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RASCOL, Olivier
BouNDless, NCT04006210 / 2018-004156-37: Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

Active, not recruiting
3
381
Europe, US, RoW
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, IR-LD/CD, Placebo for Oral IR-LD/CD, Placebo for IR-LD/CD
NeuroDerm Ltd.
Parkinson's Disease
11/22
02/27
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Completed
2
117
Europe
Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN, ACADIA Pharmaceuticals Inc.
Parkinson Disease
04/24
06/24
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
LUMA, NCT05348785 / 2021-004849-20: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
ECOSO-iCARE-PD, NCT04485468: Integrated Parkinson Care Networks: Assessment of Economics and Socials Barriers

Completed
N/A
72
Europe
Questionnaire
University Hospital, Toulouse
Parkinson Disease
07/21
07/21
ICARE-PD, NCT04915209: Integrated Parkinson Care Networks : Care in Parkinson Disease

Not yet recruiting
N/A
50
Europe
Narrative interviews
University Hospital, Toulouse
Parkinson Disease
12/21
12/22
ASPIRE-MSA, NCT04229173: Natural History and Disease Progression Biomarkers of Multiple System Atrophy

Completed
N/A
61
Europe
MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional), Evaluations about motor abilities, depression, cognition and lifestyle, Evaluation about depression cognition
University Hospital, Toulouse
Multiple System Atrophy
05/22
10/22
BIOPARK, NCT02114242: Biomarkers in Parkinsonian Syndromes

Recruiting
N/A
100
Europe
CSF, blood and urine sampling, clinical measures of disease severity and progression
University Hospital, Bordeaux
Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
12/23
12/25
dBM-DEV, NCT06444789: AI-PROGNOSIS - Digital Biomarkers Development Study

Not yet recruiting
N/A
90
Europe
connected smartwatch
University Hospital, Toulouse, European Union, University Hospital Carl Gustav Carus, Aristotle University Of Thessaloniki
Parkinson Disease
07/25
07/25
RETRO-PIMPARK, NCT06754553: Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not yet recruiting
N/A
100
Europe
Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK Network, EUCLID Clinical Trial Platform, F-CRIN
Parkinson Disease
02/26
02/26
PSYCHO-PAIN, NCT05713500: Comparative Study of Personality in Parkinson's Disease Patients With Other Chronic Pain

Completed
N/A
100
Europe
TCI, BPI, CPAQ-8, SF-MPQ, King's Parkinson's Disease Pain Scale (KPPS), Hospital Anxiety and Depression scale (HAD) questionary, PCS, ORT, Social Support Questionnaire (SSQ6), IPQ-R, WCC-R
University Hospital, Toulouse
Parkinson Disease
04/24
04/24

Download Options